Sugi Predict

Sugi Predict / Compounds / SCHEMBL1075359

SCHEMBL1075359

SCHEMBL1075359

N#Cc1ccc(NC(=O)N2CCC(C(=O)Nc3ccc4cc3CCc3cccc(c3)Nc3ncc(Cl)c(n3)N4)CC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 10/20 0.50
▸ TRPM8 Q7Z2W7 1/20 0.43
▸ MEN1 O00255 1/20 0.38
▸ USP2 O75604 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ STK4 Q13043 1/20 0.37
▸ STK3 Q13188 1/20 0.37
▸ STK26 Q9P289 1/20 0.37
▸ STK24 Q9Y6E0 1/20 0.37
▸ JAK2 O60674 6/20 0.37
▸ JAK1 P23458 6/20 0.37
▸ TYK2 P29597 6/20 0.37
▸ JAK3 P52333 6/20 0.37
▸ IDO1 P14902 1/20 0.36
▸ MALT1 Q9UDY8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4364896 0.96 ALK (0.46) ALKTRPM8MEN1USP2MAPT
SCHEMBL1075366 0.92 ALK (0.52) ALKSTK4STK3STK26STK24
SCHEMBL1074407 0.91 ALK (0.51) ALKSTK4STK3STK26STK24
SCHEMBL13632926 0.91 ALK (0.50) ALKSTK4STK3STK26STK24
SCHEMBL4356258 0.90 ALK (0.50) ALKSTK4STK3STK26STK24
Trifluoroacetic Acid SCHEMBL4362007 0.88 ALK (0.48) ALKTRPM8STK4STK3STK26
SCHEMBL1075119 0.88 ALK (0.51) ALKKMT2ASTK4STK3STK26
SCHEMBL1072593 0.86 ALK (0.55) ALKSTK4STK3STK26STK24
SCHEMBL1076850 0.86 ALK (0.67) ALKTRPM8STK4STK3STK26
SCHEMBL4360904 0.86 ALK (0.54) ALKSTK4STK3STK26STK24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 — — US claimed
EP-2274288-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS Incyte Corporation (US) 2011-01-19 — — EP claimed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 — — US claimed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 — — WO claimed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 — — US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 — — US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK ALK 3/4885TRPM8 2927/4885MEN1 1321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.